A new version of a screening test for ovarian cancer may reduce deaths from the disease, but it needs more study to determine whether the benefits hold up, researchers reported on Thursday. The findings come from a 14-year study of more than 200,000 women in Britain, published in The Lancet. "We need to follow up to confirm that this is absolutely significant throughout," said Dr. Usha Menon, an author of the Lancet article and head of the gynecological cancer center at University College London. She said, "This is almost there, but not yet."